rs1341162 — CYP2C8

Intronic CYP2C8 haplotype-tagging variant linked to altered drug metabolism capacity and bisphosphonate-related osteonecrosis of the jaw risk

See your personal result for CYP2C8

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP2C8 Intron 5 — A Haplotype Tag with Drug and Bone Consequences

CYP2C8 is one of the body's principal drug-processing enzymes, responsible for clearing roughly 5% of all commonly prescribed medications. Its substrates span remarkably diverse drug classes: the antidiabetics repaglinide and rosiglitazone, the chemotherapy agent paclitaxel, the antimalarial amodiaquine, and several NSAIDs including ibuprofen. Beyond drug metabolism, CYP2C8 converts arachidonic acid into [epoxyeicosatrienoic acids (EETs) | lipid signaling molecules with vasodilating, anti-inflammatory, and bone-protective properties], making CYP2C8 activity relevant far outside the pharmacy.

rs1341162 sits in intron 5 of CYP2C8 on chromosome 10 (GRCh38 position 95,050,855) and does not directly alter the enzyme's amino acid sequence. Its significance lies in what it tags: a broader intronic haplotype block that cosegregates with altered CYP2C8 expression and activity.

The Mechanism

The T allele at rs1341162 travels together with the T allele at rs193495111 rs1934951
intron 8 variant; the most strongly MRONJ-associated CYP2C8 SNP and the T allele at rs1934980, forming the "TGT" haplotype first identified by Sarasquete et al., Blood 200822 Sarasquete et al., Blood 2008
PMID 18594024. This haplotype was present in 45% of bisphosphonate-treated multiple myeloma patients who developed osteonecrosis of the jaw, compared with only 10% of controls — an odds ratio exceeding 7. The complementary "CAC" haplotype (the C allele at all three positions) was the protective common form (83% in controls vs 50% in cases).

The exact molecular mechanism by which intronic variants in this haplotype alter CYP2C8 function remains incompletely characterized. Intronic variants can affect [pre-mRNA splicing | intronic sequences contain regulatory elements that guide the spliceosome], create or destroy branch points, or alter regulatory elements recognized by RNA-binding proteins. Functional studies of related CYP2C8 intronic haplotypes (the "haplotype B" described by Rodríguez-Antona et al., 200733 Rodríguez-Antona et al., 2007
PMID 17923851) showed significantly increased paclitaxel 6α-hydroxylation in liver microsomes, suggesting at least some intronic variants in this region do alter expression or splicing.

The Bisphosphonate Connection

The leading hypothesis connecting CYP2C8 to [medication-related osteonecrosis of the jaw (MRONJ) | jaw bone death complicating bisphosphonate treatment in ~5% of cancer patients receiving high-dose IV therapy] is EET-mediated. CYP2C8 produces EETs from arachidonic acid, and EETs have been shown to directly suppress osteoclast formation, inhibit NF-κB and RANKL signaling in bone cells, and reduce inflammatory cytokines (TNF-α, IL-1β) that drive bone resorption (Norwood et al., 201444 Norwood et al., 2014
PMID 25466887). If the TGT haplotype reduces CYP2C8 activity and lowers EET output in jaw bone, it may create a permissive inflammatory environment in which the additional bone-metabolic stress of bisphosphonates — which suppress osteoclast renewal, impair angiogenesis, and trap necrotic fragments — tips into clinical necrosis.

The Evidence

The discovery study by Sarasquete et al. used 500,568 SNPs across 22 multiple myeloma cases with MRONJ and 65 matched controls; rs1341162 reached p = 6.22 × 10⁻⁶ (below the Bonferroni-corrected threshold of p = 1 × 10⁻⁷ for that array). The stronger signal came from rs1934951 (p = 1.07 × 10⁻⁶; OR 12.75), which is in strong LD with rs1341162. A replication study by Such et al. (Haematologica, 2011; PMID 2168547455 PMID 21685474) in 79 myeloma patients could not confirm a statistically significant association, illustrating the modest statistical power of these relatively small cohorts. A meta-analysis of rs1934951 (the lead SNP in this block) found pooled OR ~3.2 across available studies, consistent with a real but attenuated effect (PMID 2317185666 PMID 23171856).

For the drug-metabolism dimension, intronic CYP2C8 haplotypes shift paclitaxel, repaglinide, and amodiaquine pharmacokinetics in population studies, though the effect size is smaller than for the nonsynonymous CYP2C8*3 allele (rs10509681 + rs11572080). The evidence level for rs1341162 specifically is moderate — the haplotype association is replicated but the mechanistic connection remains incompletely resolved.

Practical Actions

Carriers of the TT genotype (approximately 9% globally, 4% in Europeans) carry the full dose of the risk haplotype. For patients facing bisphosphonate treatment — particularly high-dose intravenous therapy with zoledronic acid or pamidronate for multiple myeloma or bone metastases — knowledge of this variant status provides an early signal to intensify dental surveillance before starting treatment. For oncologists managing paclitaxel-based regimens, CYP2C8 haplotype status may be one factor to consider alongside the more established CYP2C8*3 genotype when calibrating dose-related neuropathy risk.

Interactions

rs1341162 is part of a broader intronic haplotype block with rs1934951 and rs1934980. Its effects compound with the nonsynonymous CYP2C8*3 allele (defined by rs11572080 and rs10509681), which reduces enzyme activity to ~50% of wild-type. Individuals carrying both the TGT intronic haplotype and one or two CYP2C8*3 alleles have the most reduced CYP2C8 capacity and, in theory, the greatest MRONJ and drug-accumulation risk.

Drug Interactions

zoledronic acid increased_toxicity literature
pamidronate increased_toxicity literature
paclitaxel dose_adjustment literature
repaglinide dose_adjustment literature
rosiglitazone dose_adjustment literature
amodiaquine dose_adjustment literature
ibuprofen dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal Haplotype Normal

Common CYP2C8 haplotype — standard drug metabolism

You carry two copies of the common C allele at rs1341162, placing you on the protective "CAC" CYP2C8 haplotype. About 48% of people globally share this genotype, rising to roughly 64% among people of European descent. Your CYP2C8 intronic haplotype does not confer elevated risk for bisphosphonate-related osteonecrosis of the jaw, and your drug metabolism through this enzyme is unaffected by this variant. Note that other CYP2C8 variants (particularly the *3 allele at rs11572080) are assessed separately and have larger, better-characterized pharmacogenomic effects.

CT Heterozygous Risk Haplotype Intermediate

One copy of the CYP2C8 intronic risk haplotype

The TGT haplotype (tagging the T alleles at rs1934951, rs1934980, and rs1341162) was found in 45% of MRONJ cases vs 10% of controls in the Sarasquete 2008 study (Blood, PMID 18594024). One copy of the risk haplotype places you in an intermediate risk category. The mechanism likely involves altered CYP2C8-mediated production of epoxyeicosatrienoic acids (EETs) in jaw bone — EETs normally suppress osteoclast activity and bone inflammation, so reduced output may increase susceptibility to the bone-remodeling disruption caused by bisphosphonates.

Replication evidence is mixed (Such et al. 2011 could not confirm the association in a smaller cohort), so the finding should be considered in clinical context rather than as a deterministic risk predictor.

TT Homozygous Risk Haplotype High Risk

Two copies of the CYP2C8 intronic risk haplotype

The TT genotype at rs1341162 corresponds to homozygosity for the CYP2C8 TGT intronic haplotype, which disrupts normal CYP2C8 expression or splicing regulation. This likely reduces the enzyme's capacity to produce epoxyeicosatrienoic acids (EETs) from arachidonic acid. EETs are potent anti-inflammatory, vasodilating lipid mediators that also directly inhibit osteoclast formation via NF-κB suppression.

For bisphosphonate therapy: the absolute risk of MRONJ in the general population receiving IV bisphosphonates for cancer is approximately 1-10%. Even with the elevated CYP2C8 haplotype risk, MRONJ remains preventable with proper dental care before and during therapy. However, this genotype warrants proactive management rather than watchful waiting.

For drug metabolism: homozygous TGT carriers metabolize CYP2C8 substrates differently than wild-type individuals. The degree of change is smaller than that of the CYP2C8*3 allele (which directly alters the enzyme's active site) but may still cause clinically meaningful differences in drug exposure for sensitive substrates like repaglinide and paclitaxel, particularly when combined with *3 alleles on the other chromosome.